Sartorius Stedim Biotech S.A.
SRTOY
Other OTC20.60
USD
+0.27
- -
ISIN
US80386Y1010
CUSIP
80386Y101
Return %
Stock
S&P500
1Y
-3.69
26.53
3Y
-24.68
76.60
5Y
-52.65
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Rene Faber
- Full Time Employees
- 9,961
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- Zone Industrielle Les Paluds Aubagne France 13781
- IPO Date
- Feb 9, 2022
- Website
- sartorius.com
- Similar Companies
- Business
- Sartorius Stedim Biotech S.A. (SRTOY) serves as a leading international partner to the biopharmaceutical industry, providing equipment, consumables and services that support the development, quality assurance and production of biotech medications and vaccines; its comprehensive portfolio spans the entire bioprocess value chain, including cell line technologies, cell culture media, single-use bioreactors such as Biostat STR, membrane chromatography devices, filtration and purification systems like tangential flow filtration, concentration solutions, fluid management products including single-use bags for storage and transportation, laboratory equipment such as analytical balances and pipettes, as well as process development tools and testing services. The company operates two primary segments, Bioprocess Solutions which accounts for the majority of revenue through technologies for fermentation, cell cultivation, separation and purification, and Lab Products & Services offering consumables and instruments for research; it targets biopharmaceutical manufacturers, biotech firms and laboratories across therapeutic areas including oncology, immunology, rare diseases and cell and gene therapies, with subsidiaries in more than 30 countries, key production and R&D sites in Europe, North America and Asia-Pacific, around 10,600 employees worldwide, and headquarters in Aubagne, France, where the parent Sartorius Stedim Biotech S.A. -- majority-owned by Sartorius AG of Göttingen, Germany -- was formed through the 2007 acquisition of Stedim by Sartorius AG and listed on Euronext Paris. Among its latest major developments, Sartorius Stedim Biotech completes a multi-year capacity expansion at its Aubagne headquarters in June 2025, adding manufacturing facilities for fluid management technologies, a 1,900-square-meter cross-functional lab for product development in cell culture and customer training, and enhanced automation and sustainability features; it expands production of key components for cell and gene therapies at its Strasbourg-Illkirch site in France with over 3,000 square meters of new GMP-grade area for chemical synthesis, formulation, fill-finish and quality control, hiring 20 additional employees; in August 2025, it invests up to $3 million for a minority stake in U.S.-based Nanotein Technologies, securing exclusive global distribution of NanoSpark STEM-T and GROW-NK reagents for T-cell and NK-cell activation in CAR-T and cancer therapies while collaborating on new cell and gene therapy solutions; earlier, in April 2023, its parent Sartorius AG acquires Polyplus for €2.4 billion to bolster transfection reagents and plasmid DNA capabilities, with the Illkirch facility set to add two multi-modality GMP suites in 2025 for clinical production support.